Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Cholestasis D002779 23 associated lipids
Fibrosis D005355 23 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Multiple Sclerosis D009103 13 associated lipids
Glomerulonephritis D005921 35 associated lipids
Nervous System Diseases D009422 37 associated lipids
Psoriasis D011565 47 associated lipids
Brain Edema D001929 20 associated lipids
Leukopenia D007970 9 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Staphylococcal Skin Infections D013207 9 associated lipids
Burns, Inhalation D002059 4 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Fetal Weight D020567 12 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemia D007511 18 associated lipids
Colonic Diseases D003108 5 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Macconi D et al. Defective platelet aggregation in response to platelet-activating factor in uremia associated with low platelet thromboxane A2 generation. 1992 Am. J. Kidney Dis. pmid:1562019
Tetta C et al. Relevance of platelet-activating factor in inflammation and sepsis: mechanisms and kinetics of removal in extracorporeal treatments. 1997 Am. J. Kidney Dis. pmid:9372980
Hall AV et al. Abrogation of MRL/lpr lupus nephritis by dietary flaxseed. 1993 Am. J. Kidney Dis. pmid:8352261
Gallego MJ et al. Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. 1996 Am. J. Kidney Dis. pmid:8712218
Xu H et al. Platelet-activating factor acetylhydrolase gene mutation in Japanese children with Escherichia coli O157-associated hemolytic uremic syndrome. 2000 Am. J. Kidney Dis. pmid:10873870
Hollister AS et al. Humoral factor, intraplatelet calcium, and hypertension. 1992 Am. J. Hypertens. pmid:1632935
Verhoef G and Boogaerts M Treatment with granulocyte-macrophage colony stimulating factor and the adult respiratory distress syndrome. 1991 Am. J. Hematol. pmid:1672790
Rao AK et al. Platelet-activating factor is a weak platelet agonist: evidence from normal human platelets and platelets with congenital secretion defects. 1984 Am. J. Hematol. pmid:6431801
Issekutz AC and Ripley M The effect of intravascular neutrophil chemotactic factors on blood neutrophil and platelet kinetics. 1986 Am. J. Hematol. pmid:2934975
Radhika V et al. Granulocytes from chronic myeloid leukemia (CML) patients show differential response to different chemoattractants. 1996 Am. J. Hematol. pmid:8756080
Lo GK et al. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? 2007 Am. J. Hematol. pmid:17722079
Marx G et al. Nutritional zinc increases platelet reactivity. 1991 Am. J. Hematol. pmid:1951315
Pelczar-Wissner CJ et al. Absence of platelet activating factor (PAF) mediated platelet aggregation: a new platelet defect. 1984 Am. J. Hematol. pmid:6720685
Yoshida H et al. Activity of platelet-activating factor acetylhydrolase exists in red cell membrane. 1992 Am. J. Hematol. pmid:1566749
Greinacher A Too many hits in HIT? 2007 Am. J. Hematol. pmid:17729242
Sandberg-Gertzén H An open trial of Cedemin, a Gingko biloba extract with PAF-antagonistic effects for ulcerative colitis. 1993 Am. J. Gastroenterol. pmid:8470656
Braquet P Cedemin, a Ginkgo biloba extract, should not be considered as a PAF antagonist. 1993 Am. J. Gastroenterol. pmid:8110248
Sandler RM et al. Heparin-induced thrombocytopenia and thrombosis: detection and specificity of a platelet-aggregating IgG. 1985 Am. J. Clin. Pathol. pmid:4003343
Prescott SM What are the effects of dietary fatty acid modification on platelet eicosanoid metabolism, platelet-activating factor, and platelet function? How might these metabolic alterations influence thrombosis? 1992 Am. J. Clin. Nutr. pmid:1414987
Zhang C et al. The effect of Ginkgo biloba extract (EGb 761) on hepatic sinusoidal endothelial cells and hepatic microcirculation in CCl4 rats. 2004 Am. J. Chin. Med. pmid:15154282
Kwiterovich PO The antiatherogenic role of high-density lipoprotein cholesterol. 1998 Am. J. Cardiol. pmid:9819099
Madsen NJ et al. Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents. 2007 Am. J. Cardiol. pmid:17697836
Shohet RV et al. Plasma platelet-activating factor acetylhydrolase activity is not associated with premature coronary atherosclerosis. 1999 Am. J. Cardiol. pmid:10073795
Ambrosio G and Tritto I Reperfusion injury: experimental evidence and clinical implications. 1999 Am. Heart J. pmid:10426862
Maruyama M et al. Evidence for a role of platelet activating factor in the pathogenesis of irreversible but not reversible myocardial injury after reperfusion in dogs. 1990 Am. Heart J. pmid:2389687
Schwinger RH et al. Existence of PAF receptors in human platelets and human lung tissue but not in the human myocardium. 1992 Am. Heart J. pmid:1322030
Liu Q et al. The effect of lexipafant on bacterial translocation in acute necrotizing pancreatitis in rats. 1999 Am Surg pmid:10399968
Hebra A et al. Systemic and mesenteric vascular effects of platelet-activating factor and cocaine. In vivo effects on a neonatal swine model. 1993 Am Surg pmid:8480932
Cingi C et al. The histopathological effect of thymoquinone on experimentally induced rhinosinusitis in rats. 2011 Nov-Dec Am J Rhinol Allergy pmid:22185737
Muñoz-Cano R et al. Platelet-activating factor nasal challenge induces nasal congestion and reduces nasal volume in both healthy volunteers and allergic rhinitis patients. 2013 Mar-Apr Am J Rhinol Allergy pmid:23562190
Adamson LM et al. Mechanistic studies of early pregnancy associated thrombocytopenia (EPAT) in the mouse. 1987 Am J Reprod Immunol Microbiol pmid:3605486
Müllers SM et al. Altered Platelet Function in Intrauterine Growth Restriction: A Cause or a Consequence of Uteroplacental Disease? 2016 Am J Perinatol pmid:26906182
Sills RH Thrombotic thrombocytopenic purpura. I. Pathophysiology and clinical manifestations. 1984 Am J Pediatr Hematol Oncol pmid:6442830
McKenna DJ et al. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. 2001 Sep-Oct Altern Ther Health Med pmid:11565403
Coleus forskohlii. Monograph. 2006 Altern Med Rev pmid:16597194
Gleich GJ and Abu-Ghazaleh R Update on eosinophils. 1989 Jan-Feb Allergy Proc pmid:2925087
Chung KF et al. Platelet activating factor: effects on bronchomotor tone and bronchial responsiveness in human beings. 1989 Sep-Oct Allergy Proc pmid:2684754
Nabe M et al. The effect of ketotifen on eosinophils as measured at LTC4 release and by chemotaxis. 1991 Jul-Aug Allergy Proc pmid:1936977
Rosenwasser L New insights into the pathophysiology of allergic rhinitis. 2007 Jan-Feb Allergy Asthma Proc pmid:17390750
Klettke U et al. Platelet-activating factor inhibits ciliary beat frequency of human bronchial epithelial cells. 1999 Mar-Apr Allergy Asthma Proc pmid:10209689
Babayigit A et al. Effects of Ginkgo biloba on airway histology in a mouse model of chronic asthma. 2009 Mar-Apr Allergy Asthma Proc pmid:19118503
Oxholm P and Winther K Thrombocyte involvement in immune inflammatory reactions. 1986 Allergy pmid:3515999
Kurosawa M et al. Increased levels of blood platelet-activating factor in bronchial asthmatic patients with active symptoms. 1994 Allergy pmid:8198242
Mishra RK et al. Differential dependence of eosinophil chemotactic responses on phosphoinositide 3-kinase (PI3K). 2005 Allergy pmid:16076309
Mullol J et al. Update on rupatadine in the management of allergic disorders. 2015 Allergy pmid:25491409
Schauer U et al. Enhanced production of platelet activating factor by peripheral granulocytes from children with asthma. 1992 Allergy pmid:1514664
Egesten A and Malm J Eosinophil leukocyte degranulation in response to serum-opsonized beads: C5a and platelet-activating factor enhance ECP release, with roles for protein kinases A and C. 1998 Allergy pmid:9860239
Woo HY et al. Mechanism for acute oral desensitization to antibiotics. 2006 Allergy pmid:16867049
Howarth PH Mediators of nasal blockage in allergic rhinitis. 1997 Allergy pmid:9353555
Zuberbier T et al. Histamine releasability of basophils and skin mast cells in chronic urticaria. 1996 Allergy pmid:8721524
Zeck-Kapp G et al. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations. 1995 Allergy pmid:7741187
Krause K et al. Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. 2013 Allergy pmid:23320562
Bachert C Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. 2001 Allergy pmid:11243500
Oxholm P et al. Lack of evidence for human lymphokines with thrombocyte aggregating activity. An in vitro study. 1984 Allergy pmid:6528957
Dunoyer-Geindre S et al. PAF acether release on antigenic challenge. A method for the investigation of drug allergic reactions. 1992 Allergy pmid:1590567
Mullol J et al. Rupatadine in allergic rhinitis and chronic urticaria. 2008 Allergy pmid:18339040
Juhlin L A comparison of the pharmacodynamics of H1-receptor antagonists as assessed by the induced wheal-and-flare model. 1995 Allergy pmid:7645678
Meltzer EO The use of anti-H1 drugs in mild asthma. 1995 Allergy pmid:7645681
Pipkorn U et al. Effect of platelet activating factor on the human nasal mucosa. 1984 Allergy pmid:6703263
Takafuji S et al. Effects of interleukin (IL)-3 and IL-5 on human eosinophil degranulation induced by complement components C3a and C5a. 1996 Allergy pmid:8874660
Di Leo E et al. Treatment of acquired cold urticaria with rupatadine. 2009 Allergy pmid:19392988
Soyombo O et al. Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine. 1994 Allergy pmid:8037356
Takafuji S et al. Release of granule proteins from human eosinophils stimulated with mast-cell mediators. 1998 Allergy pmid:9821474
Maniscalco M et al. The effect of platelet-activating factor (PAF) on nasal airway resistance in healthy subjects is not mediated by nitric oxide. 2000 Allergy pmid:10955702
Leggieri E et al. Study of the effects of paf-acether on human nasal airways. 1991 Allergy pmid:1720286
Mukai K et al. New insights into the roles for basophils in acute and chronic allergy. 2009 Allergol Int pmid:19153532
Negro Alvarez JM et al. Platelet-activating factor antagonists. 1997 Sep-Oct Allergol Immunopathol (Madr) pmid:9395010
Monteseirín J et al. Formation of lipids, peptides and cytokines. 1996 Sep-Oct Allergol Immunopathol (Madr) pmid:8985477
Miadonna A et al. Induction and control of allergic inflammation in human respiratory airways. 1993 May-Jun Allergol Immunopathol (Madr) pmid:7689291
Rihoux JP [Allergic reaction and vascular permeability]. 1990 Allerg Immunol (Paris) pmid:2288644
Beauvais F and Benveniste J [IgE and anaphylaxis mediators]. 1987 Allerg Immunol (Paris) pmid:2968802
Mencia-Huerta JM et al. [Effect of long-term administration of platelet activating factor on pulmonary response and morphology in the guinea pig]. 1988 Allerg Immunol (Paris) pmid:3245884
Ligumsky M et al. The role of platelet activating factor [correction of actor] in acute gastric injury and its protection by sucralfate. 1990 Aliment. Pharmacol. Ther. pmid:2129638
Greenberg SS et al. Ethanol suppresses endotoxin but not platelet activating factor-induced hypotension and nitric oxide. 1996 Alcohol. Clin. Exp. Res. pmid:8904980
Saleh AA et al. Effect of alcohol on platelet-activating factor acetylhydrolase activity in pregnant and nonpregnant mice. 1994 Alcohol. Clin. Exp. Res. pmid:7978079
Baker RC et al. Effects of ethanol on human platelets stimulated with platelet-activating factor, a biologically active ether phospholipid. 1989 Alcohol. Clin. Exp. Res. pmid:2557776
Lands WE Cellular signals in alcohol-induced liver injury: a review. 1995 Alcohol. Clin. Exp. Res. pmid:7485841
Kelesidis T et al. The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection. AIDS Rev pmid:26616844
Chini M et al. Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen. 2012 AIDS Res. Hum. Retroviruses pmid:22050695
Lima RG et al. Interaction of macrophages with apoptotic cells enhances HIV Type 1 replication through PGE2, PAF, and vitronectin receptor. 2006 AIDS Res. Hum. Retroviruses pmid:16910832
Tsoupras AB et al. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? 2008 AIDS Res. Hum. Retroviruses pmid:18620493
Bertrand C et al. Selective implication of thromboxane A2 and PAF-acether in two guinea pig anaphylactic models. 1990 Agents Actions Suppl. pmid:2080755
Tsunoda H et al. Effects of a novel PAF antagonist, E6123, on PAF-induced biological responses. 1990 Agents Actions Suppl. pmid:2080757
Sakuma Y et al. Effects of a novel PAF antagonist, E6123, on passive anaphylaxis. 1990 Agents Actions Suppl. pmid:2080758
Rihoux JP The inhibiting effect of cetirizine 2 HC1 on eosinophil migration and its link to H1 blockade. 1991 Agents Actions Suppl. pmid:1675836
Goldie RG et al. PAF receptors in guinea-pig and human lung. 1990 Agents Actions Suppl. pmid:1964365
Alabaster VA et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. 1991 Agents Actions Suppl. pmid:1793066
Heuer HO The effects of hetrazepine PAF antagonists in preclinical models of asthma. 1991 Agents Actions Suppl. pmid:1793067
Mazzoni L et al. Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. 1991 Agents Actions Suppl. pmid:1793069
Billah MM et al. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. 1991 Agents Actions Suppl. pmid:1793070
Saeed SA et al. Inhibitory effect of oral ketotifen on ex vivo platelet activating factor-induced platelet aggregation. 1991 Agents Actions Suppl. pmid:1793071
Anderson GP and Fennessy MR Lipoxygenase metabolites as mediators of platelet activating factor-induced increased airways responsiveness to histamine in the guinea-pig. 1988 Agents Actions Suppl. pmid:3140616
Page CP et al. Drugs affecting pulmonary responses to platelet activating factor as novel anti-asthma drugs. 1988 Agents Actions Suppl. pmid:3051932
Hoshiko K et al. Histamine(H1) antagonists and airway hyperreactivity in the guinea-pig. 1991 Agents Actions Suppl. pmid:1686527
Muirhead EE Vasodepressor lipid of the renomedullary interstitial cells of the renal papilla is a prohormone activated by the liver. 1987 Agents Actions Suppl. pmid:3324720
Subissi A and Criscuoli M Effects of LG 30435 on different platelet activating factor-induced responses. 1988 Agents Actions Suppl. pmid:3262990
Heuer H and Casals-Stenzel J Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. 1988 Agents Actions Suppl. pmid:3262991
Stenzel H et al. Effect of the PAF-antagonist SRI 63-441 on the allergic reaction in awake dogs with natural asthma. 1987 Agents Actions Suppl. pmid:2823582
O'Flaherty JT and Wykle RL Metabolic origin and fate of platelet-activating factor. 1987 Agents Actions Suppl. pmid:2823583
Etienne A et al. Antithrombotic activity of BN 50341, a structurally new compound with anticalcic and PAF-antagonistic properties. 1986 Agents Actions Suppl. pmid:3468781